share

Mutant Idh1 Inhibitor CAS NO 1429180-08-4


Unit Price:

CAS No.:1429180-08-4

Grade:Pharmacy Grade

Content:99.9%

Brand:Customizable

Packaging:Customizable

Description

Mutant Idh1 Inhibitor CAS NO 1429180-08-4 is a potent and selective small molecule inhibitor designed to target the mutant isocitrate dehydrogenase 1 (IDH1) enzyme. This compound is critical for advancing research and development in oncology, specifically for cancers driven by IDH1 mutations, such as certain gliomas and acute myeloid leukemia (AML). It is an essential research-grade chemical for pharmaceutical R&D laboratories, academic institutions, and biotechnology companies focused on targeted cancer therapy and drug discovery.

Application

  • Oncological Research: Primary tool compound for studying the biological role and inhibition of mutant IDH1 in various cancer cell lines and models.
  • Drug Discovery & Development: Serves as a key reference standard, lead compound, or pharmacophore model in the design and screening of novel IDH1-targeted therapeutics.
  • Biochemical Assays: Used in in vitro enzymatic assays to determine IC50 values and evaluate the potency of new inhibitor candidates.
  • Preclinical Studies: Facilitates pharmacokinetic (PK), pharmacodynamic (PD), and efficacy studies in animal models of IDH1-mutant cancers.
  • Mechanism of Action (MoA) Studies: Enables research into the downstream effects of mutant IDH1 inhibition, including oncometabolite (2-HG) reduction and cellular differentiation.
  • Combinatorial Therapy Research: Investigated in combination with other anticancer agents (e.g., chemotherapy, immunotherapy) to explore synergistic effects.

Basic Information

Product Name Mutant Idh1 Inhibitor
CAS No. 1429180-08-4
Molecular Formula Contact for details
Molecular Weight Contact for details
Synonyms IDH1 Inhibitor; Mutant IDH1 Inhibitor; IDH1-R132H Inhibitor; AGI-5198; (R)-Enantiomer of AGI-5198; (R)-AGI-5198; 4-[(1R)-1-(2-Chlorophenyl)-2-hydroxyethylamino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinazoline; 1429180-08-4
EINECS Contact for details

Quality Control

Our Mutant Idh1 Inhibitor is manufactured under strict quality systems to ensure batch-to-batch consistency and high purity for research applications. Each lot undergoes comprehensive analytical testing, including HPLC for purity and identity confirmation (NMR, MS). A detailed Certificate of Analysis (COA) is provided with every shipment, documenting the exact specifications and results.

Storage

Preserve in a tightly closed container, protected from light. Store at -20°C or below under an inert atmosphere. This compound is hygroscopic (moisture-sensitive); allow the sealed vial to equilibrate to room temperature before opening to minimize moisture uptake. For long-term storage, keep desiccated.

Specification

Item Specification
Appearance White to off-white solid
Identification (HPLC) Conforms to reference standard
Identification (MS) Conforms to structure
Purity (HPLC) ≥98.0%
Water Content (KF) ≤1.0%
Residual Solvents (GC) Meets ICH guidelines

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.

Complete Your RFQ

0/ 2000

Why choose US

Trusted Manufacturer

With our own production facilities, we ensure consistent quality, reliable supply, and full traceability.

Rigorous Quality Assurance

Each batch undergoes strict QC, accompanied by COA, MSDS, and full compliance with international standards.

Advanced R&D Expertise

Our in-house lab drives process innovation, new product development, and tailored synthesis solutions.